DENTSPLY SIRONA Inc. 10-Q

Item 1 – Financial Statements DENTSPLY SIRONA INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in millions, except per share amounts) (unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Net sales $ 951 $ 947 $ 2,888 $ 2,953 Cost of products sold 456 452 1,376 1,389 Gross profit 495 495 1,512 1,564 Selling, general, and administrative expenses 390 372 1,204 1,204 Research and development expenses 40 46 123 141 Goodwill and intangible asset impairments 504 307 510 307 Restructuring and other costs 23 6 45 70 Operating loss ( 462 ) ( 236 ) ( 370 ) ( 158 ) Other income and expenses: Interest expense, net 18 19 53 61 Other (income) expense, net ( 2 ) ( 5 ) ( 10 ) 13 Loss before income taxes ( 478 ) ( 250 ) ( 413 ) ( 232 ) Provision (benefit) for income taxes 17 16 69 ( 28 ) Net loss ( 495 ) ( 266 ) ( 482 ) ( 204 ) Less: Net loss attributable to noncontrolling interests ( 1 ) — ( 2 ) ( 5 ) Net loss attributable to Dentsply Sirona $ ( 494 ) $ ( 266 ) $ ( 480 ) $ ( 199 ) Loss per common share attributable to Dentsply Sirona: Basic $ ( 2.46 ) $ ( 1.25 ) $ ( 2.35 ) $ ( 0.94 ) Diluted $ ( 2.46 ) $ ( 1.25 ) $ ( 2.35 ) $ ( 0.94 ) Weighted average common shares outstanding: Basic 201.0 211.8 204.7 212.7 Diluted 201.0 211.8 204.7 212.7 See accompanying Notes to Unaudited Interim Consolidated Financial Statements. 4 DENTSPLY SIRONA INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (in millions) (unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Net loss $ ( 495 ) $ ( 266 ) $ ( 482 ) $ ( 204 ) Other comprehensive income (loss), net of tax: Foreign currency translation gain (loss) 75 ( 64 ) 3 ( 49 ) Net (loss) gain on derivative financial instruments ( 36 ) 27 ( 5 ) 20 Total other comprehensive income (loss), net of tax 39 ( 37 ) ( 2 ) ( 29 ) Total comprehensive loss ( 456 ) ( 303 ) ( 484 ) ( 233 ) Less: Comprehensive loss attributable to noncontrolling interests ( 1 ) — ( 2 ) ( 5 ) Total comprehensive loss attributable to Dentsply Sirona $ ( 455 ) $ ( 303 ) $ ( 482 ) $ ( 228 ) See accompanying Notes to Unaudited Interim Consolidated Financial Statements. 5 DENTSPLY SIRONA INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (in millions, except share and per share amounts) (unaudited) September 30, 2024 December 31, 2023 Assets Current Assets: Cash and cash equivalents $ 296 $ 334 Accounts and notes receivable-trade, net 671 695 Inventories, net 619 624 Prepaid expenses and other current assets 335 320 Total Current Assets 1,921 1,973 Property, plant, and equipment, net 817 800 Operating lease right-of-use assets, net 150 178 Identifiable intangible assets, net 1,538 1,705 Goodwill 1,937 2,438 Other noncurrent assets 263 276 Total Assets $ 6,626 $ 7,370 Liabilities and Equity Current Liabilities: Accounts payable $ 297 $ 305 Accrued liabilities 798 749 Income taxes payable 25 49 Notes payable and current portion of long-term debt 422 322 Total Current Liabilities 1,542 1,425 Long-term debt 1,795 1,796 Operating lease liabilities 103 125 Deferred income taxes 193 228 Other noncurrent liabilities 503 502 Total Liabilities 4,136 4,076 Commitments and contingencies (Note 14) Equity: Preferred stock, $ 1.00 par value; 0.25 million shares authorized; no shares issued — — Common stock, $ 0.01 par value; 3 3 400.0 million shares authorized, and 264.5 million shares issued at September 30, 2024 and December 31, 2023 198.8 million and 207.2 million shares outstanding at September 30, 2024 and December 31, 2023 Capital in excess of par value 6,639 6,643 (Accumulated deficit) retained earnings ( 374 ) 205 Accumulated other comprehensive loss ( 638 ) ( 636 ) Treasury stock, at cost, 65.7 million and 57.3 million shares at September 30, 2024 and December 31, 2023, respectively ( 3,139 ) ( 2,922 ) Total Dentsply Sirona Equity 2,491 3,293 Noncontrolling interests ( 1 ) 1 Total Equity 2,490 3,294 Total Liabilities and Equity $ 6,626 $ 7,370 See accompanying Notes to Unaudited Interim Consolidated Financial Statements. 6 DENTSPLY SIRONA INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (in millions, except per share amounts) (unaudited) Common Stock Capital in Excess of Par Value (Accumulated Deficit) Retained Earnings Accumulated Other Comprehensive Loss Treasury Stock Total Dentsply Sirona Equity Noncontrolling Interests Total Equity Balance at December 31, 2023 $ 3 $ 6,643 $ 205 $ ( 636 ) $ ( 2,922 ) $ 3,293 $ 1 $ 3,294 Net income (loss) — — 18 — — 18 ( 1 ) 17 Other comprehensive loss — — — ( 30 ) — ( 30 ) — ( 30 ) Stock-based compensation expense — 11 — — — 11 — 11 Funding of employee stock purchase plan — — — — 3 3 — 3 Restricted stock unit distributions — ( 15 ) — — 11 ( 4 ) — ( 4 ) Cash dividends declared ($ 0.16 per share) — — ( 33 ) — — ( 33 ) — ( 33 ) Balance at March 31, 2024 $ 3 $ 6,639 $ 190 $ ( 666 ) $ ( 2,908 ) $ 3,258 $ — $ 3,258 Net loss — ( 4 ) — — ( 4 ) — ( 4 ) Other comprehensive loss — — — ( 11 ) — ( 11 ) — ( 11 ) Stock-based compensation expense — 12 — — — 12 — 12 Treasury shares purchased — — — — ( 152 ) ( 152 ) — ( 152 ) Restricted stock unit distributions — ( 20 ) — — 15 ( 5 ) — ( 5 ) Cash dividends declared ($ 0.16 per share) — — ( 34 ) — — ( 34 ) — ( 34 ) Balance at June 30, 2024 $ 3 $ 6,631 $ 152 $ ( 677 ) $ ( 3,045 ) $ 3,064 $ — $ 3,064 Net loss — — ( 494 ) — — ( 494 ) ( 1 ) ( 495 ) Other comprehensive income — — — 39 — 39 — 39 Stock-based compensation expense — 12 — — — 12 — 12 Funding of employee stock purchase plan — ( 2 ) — — 5 3 — 3 Treasury shares purchased — — — — ( 101 ) ( 101 ) — ( 101 ) Restricted stock unit distributions — ( 3 ) — — 2 ( 1 ) — ( 1 ) Restricted stock unit dividends — 1 ( 1 ) — — — — — Cash dividends declared ($ 0.16 per share) — — ( 31 ) — — ( 31 ) — ( 31 ) Balance at September 30, 2024 $ 3 $ 6,639 $ ( 374 ) $ ( 638 ) $ ( 3,139 ) $ 2,491 $ ( 1 ) $ 2,490 7 Common Stock Capital in Excess of Par Value Retained Earnings Accumulated Other Comprehensive Loss Treasury Stock Total Dentsply Sirona Equity Noncontrolling Interests Total Equity Balance at December 31, 2022 $ 3 $ 6,629 $ 456 $ ( 628 ) $ ( 2,649 ) $ 3,811 $ 1 $ 3,812 Net loss — — ( 19 ) — — ( 19 ) ( 4 ) ( 23 ) Other comprehensive income — — — 14 — 14 — 14 Stock-based compensation expense — 17 — — — 17 — 17 Funding of employee stock purchase plan — — — — 3 3 — 3 Accelerated share repurchase — ( 30 ) — — ( 121 ) ( 151 ) — ( 151 ) Restricted stock unit distributions — ( 12 ) — — 8 ( 4 ) — ( 4 ) Cash dividends declared ($ 0.14 per share) — — ( 30 ) — — ( 30 ) — ( 30 ) Balance at March 31, 2023 $ 3 $ 6,604 $ 407 $ ( 614 ) $ ( 2,759 ) $ 3,641 $ ( 3 ) $ 3,638 Net income (loss) — — 86 — — 86 ( 1 ) 85 Other comprehensive loss — — — ( 6 ) — ( 6 ) — ( 6 ) Exercise of stock options — — — — 1 1 — 1 Stock-based compensation expense — 14 — — — 14 — 14 Accelerated share repurchase — 30 — — ( 30 ) — — — Restricted stock unit dividends — — ( 1 ) — — ( 1 ) — ( 1 ) Cash dividends declared ($ 0.14 per share) — — ( 29 ) — — ( 29 ) — ( 29 ) Balance at June 30, 2023 $ 3 $ 6,648 $ 463 $ ( 620 ) $ ( 2,788 ) $ 3,706 $ ( 4 ) $ 3,702 Net loss — — ( 266 ) — — ( 266 ) — ( 266 ) Other comprehensive loss — — — ( 37 ) — ( 37 ) — ( 37 ) Stock-based compensation expense — 2 — — — 2 — 2 Funding of employee stock purchase plan — ( 1 ) — — 3 2 — 2 Restricted stock unit distributions — ( 4 ) — — 2 ( 2 ) — ( 2 ) Cash dividends ($ 0.14 per share) — — ( 30 ) — — ( 30 ) — ( 30 ) Balance at September 30, 2023 $ 3 $ 6,645 $ 167 $ ( 657 ) $ ( 2,783 ) $ 3,375 $ ( 4 ) $ 3,371 See accompanying Notes to Unaudited Interim Consolidated Financial Statements. 8 DENTSPLY SIRONA INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (in millions) (unaudited) Nine Months Ended September 30, 2024 2023 Cash flows from operating activities: Net loss $ ( 482 ) $ ( 204 ) Adjustments to reconcile net loss to net cash provided by operating activities: Depreciation 99 99 Amortization of intangible assets 162 159 Goodwill and intangible asset impairments 510 307 Deferred income taxes ( 20 ) ( 107 ) Stock-based compensation expense 35 33 Other non-cash expense 36 29 Changes in operating assets and liabilities: Accounts and notes receivable-trade, net 19 ( 31 ) Inventories, net 2 ( 45 ) Prepaid expenses and other current assets 61 ( 52 ) Other noncurrent assets ( 6 ) ( 4 ) Accounts payable ( 6 ) ( 10 ) Accrued liabilities ( 17 ) 16 Income taxes ( 15 ) ( 6 ) Other noncurrent liabilities ( 4 ) 33 Net cash provided by operating activities 374 217 Cash flows from investing activities: Capital expenditures ( 129 ) ( 109 ) Cash received on derivative contracts — 39 Cash paid on derivative contracts ( 12 ) — Other investing activities 1 1 Net cash used in investing activities ( 140 ) ( 69 ) Cash flows from financing activities: Cash paid for treasury stock ( 250 ) ( 150 ) Proceeds on short-term borrowings 99 68 Cash dividends paid ( 95 ) ( 86 ) Proceeds from long-term borrowings — 2 Repayments on long-term borrowings ( 8 ) ( 6 ) Other financing activities, net ( 10 ) ( 7 ) Net cash used in financing activities ( 264 ) ( 179 ) Effect of exchange rate changes on cash and cash equivalents ( 8 ) ( 25 ) Net decrease in cash and cash equivalents ( 38 ) ( 56 ) Cash and cash equivalents at beginning of period 334 365 Cash and cash equivalents at end of period $ 296 $ 309 See accompanying Notes to Unaudited Interim Consolidated Financial Statements. 9 DENTSPLY SIRONA Inc. and Subsidiaries NOTES TO UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS NOTE 1 – BUSINESS AND BASIS OF PRESENTATION Basis of Presentation The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and the rules of the U.S. Securities and Exchange Commission (“SEC”). In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair statement of the results for interim periods have been included. Certain prior period amounts have been reclassified to conform to current year presentation. Results for interim periods should not be considered indicative of results for a full year. These financial statements and related notes contain the accounts of DENTSPLY SIRONA Inc. and subsidiaries (“Dentsply Sirona” or the “Company”) on a consolidated basis and should be read in conjunction with the consolidated financial statements and notes included in the Company’s most recent Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on February 29, 2024 (the “2023 Form 10-K”). Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of net sales and expense during the reporting period. Actual results could differ materially from those estimates. Accounting Pronouncements Not Yet Adopted In November 2023, the FASB issued ASU No. 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,” which requires public entities to disclose information about significant expenses in their reportable segment results on both an interim and annual basis. Public entities are required to disclose significant expense categories and amounts for each reportable segment. Significant expense categories are derived from expenses that are regularly reported to an entity’s chief operating decision-maker (“CODM”) and included in a segment’s reported measures of profit or loss. Public entities are also required to disclose the title and position of the CODM and explain how the CODM uses the reported measures of profit or loss to assess segment performance. This standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and early adoption is permitted and should be applied retrospectively for all prior periods presented in the consolidated financial statements. The Company expects this ASU to only impact the Company’s disclosures with no impacts to results of operations, financial position, or cash flows. In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures,” which requires public entities to disclose additional income tax information, primarily related to the income tax rate reconciliation and income taxes paid on an annual basis. The amendment in the ASU is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in this update are effective for annual periods beginning after December 15, 2024, and early adoption is permitted and should be applied prospectively. The Company expects this ASU to only impact the Company’s disclosures with no impacts to results of operations, financial position, or cash flows. Seasonality The Company’s business is subject to quarterly fluctuations in demand due to price changes, marketing and promotional programs, management of inventory levels by distributors and other customers, and implementation of strategic initiatives, which may impact sales levels in any given period. Demand can also fluctuate based on the timing of dental tradeshows, new product introductions, and variability in dental patient traffic, which can be exacerbated by seasonal or severe weather patterns, demographic disruptions, macroeconomic conditions, or other factors. Some dental practices in certain countries may also delay purchasing equipment and restocking consumables until year-end due to tax or other financial planning reasons, which can impact the timing of the Company’s consolidated net sales, net income, and cash flows. Sales for the industry and the Company are generally strongest in the second and fourth quarters and weaker in the first and third quarters, due to the effects of the items noted above and due to the impact of holidays and vacations, particularly throughout Europe. Because of the seasonal nature of the Company’s business, the results of operations for any fiscal quarter will not necessarily be indicative of results to be expected for other quarters or a full fiscal year. 10 NOTE 2 - REVENUE Revenues are derived primarily from the sale of dental equipment and dental and healthcare consumable products. Revenues are measured as the amount of consideration the Company expects to receive in exchange for transferring goods or providing services. Net sales disaggregated by product category for the three and nine months ended September 30, 2024 and 2023 were as follows: Three Months Ended Nine Months Ended (in millions) 2024 2023 2024 2023 Equipment & Instruments $ 138 $ 148 $ 402 $ 480 CAD/CAM 131 128 367 370 Connected Technology Solutions 269 276 $ 769 $ 850 Essential Dental Solutions 369 347 $ 1,108 $ 1,110 Orthodontics 83 83 $ 276 $ 255 Implants & Prosthetics 158 169 512 526 Orthodontic and Implant Solutions 241 252 $ 788 $ 781 Wellspect Healthcare 72 72 $ 223 $ 212 Total net sales $ 951 $ 947 $ 2,888 $ 2,953 Net sales disaggregated by geographic region for the three and nine months ended September 30, 2024 and 2023 were as follows: Three Months Ended Nine Months Ended (in millions) 2024 2023 2024 2023 United States $ 374 $ 356 $ 1,089 $ 1,069 Europe 347 354 1,110 1,153 Rest of World 230 237 689 731 Total net sales $ 951 $ 947 $ 2,888 $ 2,953 Contract Assets and Liabilities The Company does not typically have contract assets in the normal course of its business. Contract liabilities, which represent billings in excess of revenue recognized, are primarily related to advanced billings for customer orthodontic aligner treatments where the performance obligation has not yet been satisfied. The Company recorded deferred revenue of $ 123 million and $ 67 million in Accrued liabilities and Other noncurrent liabilities, respectively, in the Consolidated Balance Sheets at September 30, 2024. The Company recorded deferred revenue of $ 91 million and $ 57 million in Accrued liabilities and Other noncurrent liabilities, respectively, in the Consolidated Balance Sheets at December 31, 2023. During the three and nine months ended September 30, 2024, the Company recognized approxim ately $ 14 million and $ 77 million o f net sales, respectively, which was previously deferred as of December 31, 2023. During the three and nine months ended September 30, 2023, the Company recognized approximately $ 12 million and $ 59 million, respectively, which was previously deferred as of December 31, 2022. The Company expects to recognize most of the remaining deferred revenue in net sales within the next twelve months. 11 Allowance for Doubtful Accounts Accounts and notes receivable-trade, net are stated net of allowances for doubtful accounts and trade discounts, which were $ 15 million at September 30, 2024 and $ 17 million at December 31, 2023. For the three and nine months ended September 30, 2024 and 2023, changes to the provision for doubtful accounts, including write-offs of accounts receivable that were previously reserved, were not significant. Changes to this provision are included in Selling, general, and administrative expenses in the Consolidated Statements of Operations. 12 NOTE 3 – STOCK COMPENSATION The amounts of stock compensation expense recorded in the Company's Consolidated Statements of Operations for the three and nine months ended September 30, 2024 and 2023 were as follows: Three Months Ended Nine Months Ended (in millions) 2024 2023 2024 2023 Cost of products sold $ — $ 1 $ 2 $ 3 Selling, general, and administrative expense 11 1 31 25 Research and development expense 1 1 2 3 Restructuring and other costs — ( 1 ) — 2 Total stock-based compensation expense $ 12 $ 2 $ 35 $ 33 13 NOTE 4 – COMPREHENSIVE INCOME (LOSS) Changes in Accumulated other comprehensive income (loss) (“AOCI”), net of tax, by component for the nine months ended September 30, 2024 and 2023 were as follows: (in millions) Foreign Currency Translation Gain (Loss) Gain (Loss) on Cash Flow Hedges Gain (Loss) on Net Investment and Fair Value Hedges Pension Liability Gain (Loss) Total Balance, net of tax, at December 31, 2023 $ ( 473 ) $ ( 13 ) $ ( 107 ) $ ( 43 ) $ ( 636 ) Other comprehensive (loss) income before reclassifications and tax impact ( 34 ) — 42 — 8 Tax expense ( 28 ) — ( 10 ) — ( 38 ) Other comprehensive (loss) income, net of tax, before reclassifications ( 62 ) — 32 — ( 30 ) Amounts reclassified from accumulated other comprehensive income (loss), net of tax — — — — — Net (decrease) increase in other comprehensive income ( 62 ) — 32 — ( 30 ) Balance, net of tax, at March 31, 2024 $ ( 535 ) $ ( 13 ) $ ( 75 ) $ ( 43 ) $ ( 666 ) Other comprehensive (loss) before reclassifications and tax impact ( 14 ) — ( 2 ) — ( 16 ) Tax benefit 4 — 1 — 5 Other comprehensive (loss), net of tax, before reclassifications ( 10 ) — ( 1 ) — ( 11 ) Amounts reclassified from accumulated other comprehensive income (loss), net of tax — — — — — Net (decrease) in other comprehensive income ( 10 ) — ( 1 ) — ( 11 ) Balance, net of tax, at June 30, 2024 $ ( 545 ) $ ( 13 ) $ ( 76 ) $ ( 43 ) $ ( 677 ) Other comprehensive income (loss) before reclassifications and tax impact 58 — ( 46 ) — 12 Tax benefit 17 — 10 — 27 Other comprehensive income (loss), net of tax, before reclassifications 75 — ( 36 ) — 39 Amounts reclassified from accumulated other comprehensive income (loss), net of tax — — — — — Net increase (decrease) in other comprehensive income 75 — ( 36 ) — 39 Balance, net of tax, at September 30, 2024 $ ( 470 ) $ ( 13 ) $ ( 112 ) $ ( 43 ) $ ( 638 ) 14 (in millions) Foreign Currency Translation Gain (Loss) Gain (Loss) on Cash Flow Hedges Gain (Loss) on Net Investment and Fair Value Hedges Pension Liability Gain (Loss) Total Balance, net of tax, at December 31, 2022 $ ( 522 ) $ ( 17 ) $ ( 73 ) $ ( 16 ) $ ( 628 ) Other comprehensive income (loss) before reclassifications and tax impact 6 ( 1 ) — — 5 Tax benefit 9 — — — 9 Other comprehensive income (loss), net of tax, before reclassifications 15 ( 1 ) — — 14 Amounts reclassified from accumulated other comprehensive income (loss), net of tax — — — — — Net increase (decrease) in other comprehensive income 15 ( 1 ) — — 14 Balance, net of tax, at March 31, 2023 $ ( 507 ) $ ( 18 ) $ ( 73 ) $ ( 16 ) $ ( 614 ) Other comprehensive loss before reclassifications and tax impact ( 3 ) — ( 11 ) — ( 14 ) Tax benefit 3 — 3 — 6 Other comprehensive loss, net of tax, before reclassifications — — ( 8 ) — ( 8 ) Amounts reclassified from accumulated other comprehensive income (loss), net of tax — 2 — — 2 Net increase (decrease) in other comprehensive income — 2 ( 8 ) — ( 6 ) Balance, net of tax, at June 30, 2023 $ ( 507 ) $ ( 16 ) $ ( 81 ) $ ( 16 ) $ ( 620 ) Other comprehensive (loss) income before reclassifications and tax impact ( 60 ) 1 33 — ( 26 ) Tax expense ( 4 ) — ( 8 ) — ( 12 ) Other comprehensive (loss) income, net of tax, before reclassifications ( 64 ) 1 25 — ( 38 ) Amounts reclassified from accumulated other comprehensive income (loss), net of tax — 1 — — 1 Net (decrease) increase in other comprehensive income ( 64 ) 2 25 — ( 37 ) Balance, net of tax, at September 30, 2023 $ ( 571 ) $ ( 14 ) $ ( 56 ) $ ( 16 ) $ ( 657 ) At September 30, 2024 and December 31, 2023, the cumulative tax adjustments were $ 160 million and $ 166 million, respectively, primarily related to foreign currency translation adjustments. The cumulative foreign currency translation adjustments included translation losses of $ 357 million and $ 360 million at September 30, 2024 and December 31, 2023, respectively, and cumulative losses on loans designated as hedges of net investments of $ 113 million at both September 30, 2024 and December 31, 2023. Reclassifications out of AOCI to the Consolidated Statements of Operations for the three and nine months ended September 30, 2024 and 2023 were not significant. 15 NOTE 5 – LOSS PER COMMON SHARE The computation of basic and diluted loss per common share for the three and nine months ended September 30, 2024 and 2023 was as follows: Basic loss per common share Three Months Ended Nine Months Ended (in millions, except per share amounts) 2024 2023 2024 2023 Net loss attributable to Dentsply Sirona $ ( 494 ) $ ( 266 ) $ ( 480 ) $ ( 199 ) Weighted average common shares outstanding 201.0 211.8 204.7 212.7 Basic loss per common share $ ( 2.46 ) $ ( 1.25 ) $ ( 2.35 ) $ ( 0.94 ) Diluted loss per common share Three Months Ended Nine Months Ended (in millions, except per share amounts) 2024 2023 2024 2023 Net loss attributable to Dentsply Sirona $ ( 494 ) $ ( 266 ) $ ( 480 ) $ ( 199 ) Weighted average common shares outstanding 201.0 211.8 204.7 212.7 Incremental weighted average shares from assumed exercise of dilutive options from stock-based compensation awards — — — — Total weighted average diluted shares outstanding 201.0 211.8 204.7 212.7 Diluted loss per common share $ ( 2.46 ) $ ( 1.25 ) $ ( 2.35 ) $ ( 0.94 ) Weighted average shares excluded from diluted common shares outstanding due to reported net loss for the period 0.5 1.1 0.6 1.1 Weighted average shares excluded from diluted common shares outstanding due to antidilutive nature 3.9 3.0 4.2 3.4 On November 7, 2023, the Board of Directors approved an increase to the authorized share repurchase program of $ 1.0 billion. Share repurchases may be made through open market purchases, Rule 10b5-1 plans, accelerated share repurchases, privately negotiated transactions or other transactions in such amounts and at such times as the Company considers appropriate based upon prevailing market and business conditions and other factors. At September 30, 2024, the Company had authorization to repurchase $ 1.19 billion in shares of common stock remaining under the share repurchase program. For the three and nine months ended September 30, 2024, the Company repurchased approximately 4.0 million and 9.4 million, respectively, outstanding shares of common stock through open market purchases at a cost of $ 100 million and $ 250 million, respectively. 16 NOTE 6 – SEGMENT INFORMATION The Company has four operating segments that are organized primarily by product. They generally have overlapping geographical presence, customer bases, distribution channels, and regulatory oversight with the exception of Wellspect Healthcare, which has a more discrete market and regulatory environment specific to the medical device industry. These operating segments, which also form the Company’s reportable segments, are identified in accordance with how the Company’s CODM regularly reviews financial results and uses this information to evaluate the Company’s performance and allocate resources. The Company evaluates performance of the segments based on net sales and adjusted operating income. Segment adjusted operating income is defined as operating income before income taxes and before certain corporate headquarters unallocated costs, goodwill and intangible asset impairments, restructuring and other costs, interest expense, net, other (income) expense, net, amortization of intangible assets, and depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations. Asset and other balance sheet information is not reported to the CODM. The Company’s segment information for the three and nine months ended September 30, 2024 and 2023 was as follows: Net Sales Three Months Ended Nine Months Ended (in millions) 2024 2023 2024 2023 Connected Technology Solutions $ 269 $ 276 $ 769 $ 850 Essential Dental Solutions 369 347 1,108 1,110 Orthodontic and Implant Solutions 241 252 788 781 Wellspect Healthcare 72 72 223 212 Total net sales $ 951 $ 947 $ 2,888 $ 2,953 Segment Adjusted Operating Income Three Months Ended Nine Months Ended (in millions) 2024 2023 2024 2023 Connected Technology Solutions $ 16 $ 22 $ 21 $ 54 Essential Dental Solutions 132 115 372 365 Orthodontic and Implant Solutions 24 31 108 129 Wellspect Healthcare 26 26 73 65 Segment adjusted operating income 198 194 574 613 Reconciling items expense (income): All other (a) 79 64 227 235 Goodwill and intangible asset impairments 504 307 510 307 Restructuring and other costs 23 6 45 70 Interest expense, net 18 19 53 61 Other (income) expense, net ( 2 ) ( 5 ) ( 10 ) 13 Amortization of intangible assets 54 53 162 159 Loss before income taxes $ ( 478 ) $ ( 250 ) $ ( 413 ) $ ( 232 ) (a) Includes unallocated corporate headquarters costs. 17 NOTE 7 – INVENTORIES Inventories, net were as follows: (in millions) September 30, 2024 December 31, 2023 Raw materials and supplies $ 180 $ 185 Work-in-process 78 77 Finished goods 361 362 Inventories, net $ 619 $ 624 The Company's inventory reserve was $ 104 million at September 30, 2024 and $ 107 million at December 31, 2023. 18 NOTE 8 – RESTRUCTURING AND OTHER COSTS Restructuring and other costs for the three and nine months ended September 30, 2024 and 2023 were recorded in the Consolidated Statements of Operations as follows: Three Months Ended Nine Months Ended (in millions) 2024 2023 2024 2023 Cost of products sold $ — $ — $ 1 $ 4 Selling, general, and administrative expenses 2 1 6 2 Restructuring and other costs 23 6 45 70 Total restructuring and other costs $ 25 $ 7 $ 52 $ 76 Restructuring and other costs of $ 45 million recorded in the first nine months of 2024 consisted primarily of employee severance benefits and other restructuring costs related to the plans approved by the Board of Directors of the Company on July 29, 2024 (the “2024 Plan”) and on February 14, 2023 (the “2023 Plan”). With the 2024 Plan, the Company seeks to improve operational performance and drive shareholder value creation. In connection with the 2024 Plan, which is expected to be substantially completed by the end of 2025, the Company anticipates a net reduction in the Company’s global workforce of approximately 2 % to 4 %. The proposed changes are subject to co-determination processes with employee representative groups in countries where required. Actions taken under the 2024 Plan will seek to further streamline the Company’s operations and global footprint, as well as improve alignment of the Company’s cost structure with its strategic growth objectives. As of September 30, 2024, the Company has incurred $ 24 million in restructuring charges under the 2024 Plan since its inception. In total, the Company expects to incur between $ 40 million and $ 50 million in non-recurring restructuring charges under the 2024 Plan, primarily related to employee transition, severance payments, and employee benefits, which are expected to be expensed and paid in cash in 2024 and 2025. With the 2023 Plan, the Company sought to restructure the business through a new operating model with five global business units, optimize central functions and overall management infrastructure, and implement other efforts aimed at cost savings. The 2023 Plan’s annual cost savings target of $ 200 million has been substantially met, with the benefits mostly offset in the short term by additional investments in sales personnel, the Company’s new global Enterprise Resource Planning (“ERP”) system, and other transformation initiatives. As of September 30, 2024, the Company has incurred $ 86 million in restructuring charges under the 2023 Plan since its inception, primarily related to employee transition, severance payments, employee benefits, and facility closure costs, and $ 20 million in other non-recurring costs related to restructuring activities, which mostly consist of consulting, legal, and other professional service fees. Remaining restructuring charges attributable to the 2023 Plan are not expected to be material. The estimates of the charges and expenditures that the Company expects to incur in connection with the 2024 Plan, and the timing thereof, are subject to several assumptions, including local law requirements in various jurisdictions and co-determination aspects in countries where required. Actual amounts may differ materially from estimates. In addition, the Company may incur additional charges or cash expenditures not currently contemplated due to unanticipated events that may occur, including in connection with the implementation of the 2024 Plan. 19 The liabilities associated with the Company's restructuring plans are recorded in Accrued liabilities and Other noncurrent liabilities in the Consolidated Balance Sheets. Activity in the Company’s restructuring accruals at September 30, 2024 was as follows: Severance (in millions) 2022 and Prior Plans 2023 Plans 2024 Plans Total Balance at December 31, 2023 $ 2 $ 37 $ — $ 39 Provisions — 22 24 46 Amounts applied ( 1 ) ( 33 ) ( 1 ) ( 35 ) Change in estimates — ( 3 ) — ( 3 ) Balance at September 30, 2024 $ 1 $ 23 $ 23 $ 47 Other Restructuring Costs (in millions) 2022 and Prior Plans 2023 Plans 2024 Plans Total Balance at December 31, 2023 $ 1 $ — $ — $ 1 Provisions — 2 — 2 Amounts applied — ( 2 ) — ( 2 ) Balance at September 30, 2024 $ 1 $ — $ — $ 1 The cumulative amounts for the provisions and adjustments and amounts applied for all the plans by segment were as follows: (in millions) December 31, 2023 Provisions Amounts Applied Change in Estimates September 30, 2024 Connected Technology Solutions $ 13 $ 19 $ ( 20 ) $ ( 2 ) $ 10 Essential Dental Solutions 17 11 ( 6 ) — 22 Orthodontic and Implant Solutions 9 11 ( 8 ) ( 1 ) 11 Wellspect Healthcare 1 4 ( 1 ) — 4 All Other — 3 ( 2 ) — 1 Total $ 40 $ 48 $ ( 37 ) $ ( 3 ) $ 48 20 NOTE 9 – FINANCIAL INSTRUMENTS AND DERIVATIVES Derivative Instruments and Hedging Activities The Company’s activities expose it to a variety of market risks, which primarily include the risks related to the effects of changes in foreign currency exchange rates and interest rates. These financial exposures are monitored and managed by the Company as part of its overall risk management program. The objective of this risk management program is to reduce the volatility that these market risks may have on the Company’s operating results and cash flows. The Company employs derivative financial instruments to hedge certain anticipated transactions, firm commitments, or assets and liabilities denominated in foreign currencies. Additionally, the Company utilizes interest rate swaps to convert fixed rate debt into variable rate debt or vice versa. The Company does not hold derivative instruments for trading or speculative purposes. The following summarizes the notional amounts of cash flow hedges, hedges of net investments, fair value hedges, and derivative instruments not designated as hedges for accounting purposes by derivative instrument type at September 30, 2024 and the notional amounts expected to mature during the next 12 months. (in millions) Aggregate Notional Amount Aggregate Notional Amount Maturing within 12 Months Cash Flow Hedges Foreign exchange forward contracts $ — $ — Interest rate swaps — — Total derivative instruments designated as cash flow hedges $ — $ — Hedges of Net Investments Foreign exchange forward contracts $ 888 $ 89 Cross currency basis swaps 297 — Total derivative instruments designated as hedges of net investments $ 1,185 $ 89 Fair Value Hedges Interest rate swaps $ 150 $ — Foreign exchange forward contracts — — Total derivative instruments designated as fair value hedges $ 150 $ — Derivative Instruments not Designated as Hedges Foreign exchange forward contracts $ 830 $ 830 Total derivative instruments not designated as hedges $ 830 $ 830 Cash Flow Hedges Foreign Exchange Risk Management The Company hedges select anticipated foreign currency cash flows to reduce volatility in both cash flows and reported earnings or losses. The Company designates certain foreign exchange forward contracts as cash flow hedges. As a result, the Company records the fair value of the contracts through AOCI based on the assessed effectiveness of the foreign exchange forward contracts. The Company measures the effectiveness of cash flow hedges of anticipated transactions on a spot-to-spot basis rather than on a forward-to-forward basis. Accordingly, the spot-to-spot change in the derivative fair value is deferred in AOCI and released and recorded in the Consolidated Statements of Operations in the same period that the hedged transaction is recorded. The time-value component of the fair value of the derivative is reported on a straight-line basis in Cost of products sold in the Consolidated Statements of Operations in the period which it is applicable. Any cash flows associated with these instruments are included in operating activities in the Consolidated Statements of Cash Flows. 21 These foreign exchange forward contracts generally have maturities up to 18 months, which is the period over which the Company is hedging exposures to variability of cash flows, and the counterparties to the transactions are large international financial institutions. Interest Rate Risk Management The Company enters into interest rate swap contracts to manage interest rate risk on long-term debt instruments and not for speculative purposes. Any cash flows associated with these instruments are included in operating activities in the Consolidated Statements of Cash Flows. On May 26, 2020, the Company paid $ 31 million to settle the $ 150 million notional Treasury rate lock contract, which partially hedged the interest rate risk of the $ 750 million Senior Notes due June 2030. This loss is amortized over the ten-year life of the notes. As of September 30, 2024 and December 31, 2023, $ 17 million and $ 19 million, respectively, of this loss is remaining to be amortized from AOCI in future periods. AOCI Release Overall, the derivatives designated as cash flow hedges are considered to be highly effective for accounting purposes. At September 30, 2024, the Company expects to reclassify $ 3 million of deferred net losses on cash flow hedges recorded in AOCI in the Consolidated Statements of Operations during the next 12 months. For the rollforward of derivative instruments designated as cash flow hedges in AOCI, see Note 4, Comprehensive Income (Loss). Hedges of Net Investments in Foreign Operations The Company has significant investments in foreign subsidiaries. The net assets of these subsidiaries are exposed to volatility in foreign currency exchange rates. The Company employs both derivative and non-derivative financial instruments to hedge a portion of these exposures. The derivative instruments consist of foreign exchange forward contracts and cross-currency basis swaps. The non-derivative instruments consist of foreign currency denominated debt held at the parent company level. Translation gains and losses related to the net assets of the foreign subsidiaries are offset by gains and losses in the aforementioned instruments, which are designated as hedges of net investments, and the intrinsic value changes in these instruments are recorded on AOCI, net of tax effects. The time-value component of the fair value of the derivative instrument is amortized on a straight-line basis in Other (income) expense, net in the Consolidated Statements of Operations in the applicable period. Any cash flows associated with these instruments are included in investing activities in the Consolidated Statements of Cash Flows, except for derivative instruments that include an other-than-insignificant financing element, for which all cash flows are classified as financing activities in the Consolidated Statements of Cash Flows. The fair value of the foreign currency exchange forward contracts and cross-currency basis swaps is the estimated amount the Company would receive or pay at the reporting date, taking into account the effective interest rates and foreign exchange rates. The effective portion of the change in the value of these derivatives is recorded in AOCI, net of tax effects. Fair Value Hedges Foreign Exchange Risk Management The Company has intercompany loans denominated in Swedish kronor that are exposed to volatility in foreign currency exchange rates. The Company employs derivative financial instruments to hedge these exposures. The Company accounts for these designated foreign exchange forward contracts as fair value hedges. The Company measures the effectiveness of fair value hedges of anticipated transactions on a spot-to-spot basis rather than on a forward-to-forward basis. Accordingly, the spot-to-spot change in the derivative fair value will be recorded in Other (income) expense, net in the Consolidated Statements of Operations. The time-value component of the fair value of the derivative is reported on a straight-line basis in Other (income) expense, net in the Consolidated Statements of Operations in the applicable period. Any cash flows associated with these instruments are included in operating activities in the Consolidated Statements of Cash Flows. Interest Rate Risk Management On February 13, 2024, the Company paid $ 9 million to settle the variable interest rate swap with a notional amount of $ 100 million which was originally set to mature on June 1, 2026. This closure of the interest rate swap will result in a loss of $ 8 million being amortized over the remaining life of the Senior Notes due June 2030. 22 Derivative Instruments Not Designated as Hedges The Company enters into derivative instruments with the intent to partially mitigate the foreign exchange revaluation risk associated with recorded assets and liabilities that are denominated in a non-functional currency. The Company primarily uses foreign exchange forward contracts to hedge these risks. The gains and losses on these derivative transactions offset the gains and losses generated by the revaluation of the underlying non-functional currency balances and are recorded in Other (income) expense, net in the Consolidated Statements of Operations. Any cash flows associated with these instruments are included in operating activities in the Consolidated Statements of Cash Flows. Gains and (losses) recorded in the Company’s Consolidated Statements of Operations related to the economic hedges not designated as hedges for the three and nine months ended September 30, 2024 and 2023 were not significant. Derivative Instrument Activity The effect of derivative hedging instruments on the Consolidated Statements of Operations and Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2024 and 2023 were as follows: Three Months Ended 2024 2023 (in millions) Cost of products sold Interest expense, net Other (income) expense, net Cost of products sold Interest expense, net Other (income) expense, net Total amounts of line items presented in the Statement of Operations in which the effects of cash flow, net investment or fair value hedges are recorded $ 456 $ 18 $ ( 2 ) $ 452 $ 19 $ ( 5 ) (Gain) loss on Cash Flow Hedges reclassified from AOCI into income Foreign exchange forward contracts $ — $ — $ — $ 1 $ — $ — Interest rate swaps — — — — — — (Gain) loss on Hedges of Net Investment Cross currency basis swaps $ — $ — $ ( 1 ) $ — $ ( 1 ) $ — Foreign exchange forward contracts — — ( 6 ) — — ( 5 ) (Gain) loss on Fair Value Hedges: Interest rate swaps $ — $ 2 $ — $ — $ 3 $ — Foreign exchange forward contracts — — — — — ( 1 ) 23 Amount of Gain or (Loss) Recognized in AOCI Amount of Gain or (Loss) Reclassified from AOCI into Income Three Months Ended Consolidated Statements of Operations Location Three Months Ended (in millions) 2024 2023 2024 2023 Cash Flow Hedges Foreign exchange forward contracts $ — $ 1 Cost of products sold $ — $ ( 1 ) Interest rate swaps — — Interest expense, net — — Hedges of Net Investments Cross currency basis swaps $ ( 8 ) $ 3 Other expense (income), net $ — $ — Foreign exchange forward contracts ( 38 ) 29 Other expense (income), net — — Fair Value Hedges Interest rate swaps $ — $ — Interest expense, net $ — $ — Foreign exchange forward contracts — 1 Other expense (income), net — — 24 Nine Months Ended 2024 2023 (in millions) Cost of products sold Interest expense, net Other expense (income), net Cost of products sold Interest expense, net Other expense (income), net Total amounts of line items presented in the Statement of Operations in which the effects of cash flow, net investment or fair value hedges are recorded $ 1,376 $ 53 $ ( 10 ) $ 1,389 $ 61 $ 13 (Gain) loss on Cash Flow Hedges reclassified from AOCI into income Foreign exchange forward contracts $ — $ — $ — $ 1 $ — $ — Interest rate swaps — 2 — — 2 — (Gain) loss on Hedges of Net Investment Cross currency basis swaps $ — $ — $ ( 3 ) $ — $ ( 3 ) $ — Foreign exchange forward contracts — — ( 19 ) — — ( 6 ) (Gain) loss on Fair Value Hedges: Interest rate swaps $ — $ 6 $ — $ — $ 8 $ — Foreign exchange forward contracts — — — — — ( 4 ) Amount of Gain or (Loss) Recognized in AOCI Amount of Gain or (Loss) Reclassified from AOCI into Income Nine Months Ended Consolidated Statements of Operations Location Nine Months Ended (in millions) 2024 2023 2024 2023 Cash Flow Hedges Foreign exchange forward contracts $ — $ — Cost of products sold $ — $ ( 1 ) Interest rate swaps — — Interest expense, net 2 ( 2 ) Hedges of Net Investments Cross currency basis swaps $ — $ ( 6 ) Other expense (income), net $ — $ — Foreign exchange forward contracts ( 5 ) 26 Other expense (income), net — — Fair Value Hedges Interest rate swaps $ — $ — Interest expense, net $ — $ — Foreign exchange forward contracts — 2 Other expense (income), net — — 25 Consolidated Balance Sheets Location of Derivative Fair Values The fair value and the financial statement presentation of the Company's derivatives in the Consolidated Balance Sheets were as follows: September 30, 2024 (in millions) Prepaid Expenses and Other Current Assets Other Noncurrent Assets Accrued Liabilities Other Noncurrent Liabilities Designated as Hedges: Foreign exchange forward contracts $ — $ — $ 2 $ 34 Interest rate swaps — — 5 11 Cross currency basis swaps 3 5 — — Total $ 3 $ 5 $ 7 $ 45 Not Designated as Hedges: Foreign exchange forward contracts $ 10 $ — $ 5 $ — Total $ 10 $ — $ 5 $ — December 31, 2023 (in millions) Prepaid Expenses and Other Current Assets Other Noncurrent Assets Accrued Liabilities Other Noncurrent Liabilities Designated as Hedges: Foreign exchange forward contracts $ 3 $ — $ 4 $ 47 Interest rate swaps — — 9 19 Cross currency basis swaps 4 4 — — Total $ 7 $ 4 $ 13 $ 66 Not Designated as Hedges: Foreign exchange forward contracts $ 5 $ — $ 5 $ — Total $ 5 $ — $ 5 $ — Balance Sheet Offsetting Substantially all of the Company’s derivative contracts are subject to netting arrangements, whereby the right to offset occurs in the event of default or termination in accordance with the terms of the arrangements with the counterparty. While these contracts contain the enforceable right to offset through netting arrangements with the same counterparty, the Company elects to present them on a gross basis in the Consolidated Balance Sheets. 26 Offsetting of financial assets and liabilities under netting arrangements at September 30, 2024 were as follows: Gross Amounts Not Offset in the Consolidated Balance Sheets (in millions) Gross Amounts Recognized Gross Amount Offset in the Consolidated Balance Sheets Net Amounts Presented in the Consolidated Balance Sheets Financial Instruments Cash Collateral Received/Pledged Net Amount Assets Foreign exchange forward contracts $ 10 $ — $ 10 $ ( 7 ) $ — $ 3 Cross currency basis swaps 8 — 8 ( 3 ) — 5 Total assets $ 18 $ — $ 18 $ ( 10 ) $ — $ 8 Liabilities Foreign exchange forward contracts $ 41 $ — $ 41 $ ( 8 ) $ — $ 33 Interest rate swaps 16 — 16 ( 2 ) — 14 Total liabilities $ 57 $ — $ 57 $ ( 10 ) $ — $ 47 Offsetting of financial assets and liabilities under netting arrangements at December 31, 2023 were as follows: Gross Amounts Not Offset in the Consolidated Balance Sheets (in millions) Gross Amounts Recognized Gross Amount Offset in the Consolidated Balance Sheets Net Amounts Presented in the Consolidated Balance Sheets Financial Instruments Cash Collateral Received/Pledged Net Amount Assets Foreign exchange forward contracts $ 8 $ — $ 8 $ ( 5 ) $ — $ 3 Cross currency basis swaps 8 — 8 ( 4 ) — 4 Total assets $ 16 $ — $ 16 $ ( 9 ) $ — $ 7 Liabilities Foreign exchange forward contracts $ 56 $ — $ 56 $ ( 7 ) $ — $ 49 Interest rate swaps 28 — 28 ( 2 ) — 26 Total liabilities $ 84 $ — $ 84 $ ( 9 ) $ — $ 75 27 NOTE 10 – FAIR VALUE MEASUREMENT The estimated fair and carrying values of the Company's total debt were $ 2,134 million and $ 2,217 million, respectively, at September 30, 2024. At December 31, 2023, the estimated fair and carrying values were $ 2,018 million and $ 2,118 million, respectively. The fair value of long-term debt is determined by discounting future cash flows using interest rates available at September 30, 2024 and December 31, 2023 and interest rates for companies with similar credit ratings for issuances with similar terms and maturities. It is considered a Level 2 fair value measurement for disclosure purposes. Assets and liabilities measured at fair value on a recurring basis The Company’s financial assets and liabilities set forth by level within the fair value hierarchy that were accounted for at fair value on a recurring basis were as follows: September 30, 2024 (in millions) Total Level 1 Level 2 Level 3 Assets Cross currency basis swaps $ 8 $ — $ 8 $ — Foreign exchange forward contracts 10 — 10 — Total assets $ 18 $ — $ 18 $ — Liabilities Interest rate swaps $ 16 $ — $ 16 $ — Foreign exchange forward contracts 41 — 41 — Contingent considerations on acquisitions 4 — — 4 Total liabilities $ 61 $ — $ 57 $ 4 December 31, 2023 (in millions) Total Level 1 Level 2 Level 3 Assets Cross currency basis swaps $ 8 $ — $ 8 $ — Foreign exchange forward contracts 8 — 8 — Total assets $ 16 $ — $ 16 $ — Liabilities Interest rate swaps $ 28 $ — $ 28 $ — Foreign exchange forward contracts 56 — 56 — Contingent considerations on acquisitions 4 — — 4 Total liabilities $ 88 $ — $ 84 $ 4 Derivative valuations are based on observable inputs to the valuation model including interest rates, foreign currency exchange rates, and credit risks. There were no transfers between fair value measurement levels during the nine months ended September 30, 2024. 28 NOTE 11 – INCOME TAXES The effective tax rates for the three months ended September 30, 2024 and 2023 were ( 3.3 %) and ( 6.3 %), respectively. For the nine months ended September 30, 2024 and 2023, the rates were ( 16.7 %) and 12.1 %, respectively. The effective tax rates for 2024 include discrete expenses resulting from implementing an internal reorganization. In contrast, the rates for 2023 were significantly affected by the partial release of the valuation allowance on net operating loss carryforwards. The Company performed an assessment to evaluate the new global minimum tax developed by the Organisation for Economic Co-operation and Development (“Pillar Two”), which involved analyzing the tax laws in each jurisdiction in which the Company operates and modeling the implications with the Pillar Two framework. The impact of Pillar Two on the Company was not significant. The Company included the impact of the top-up tax under the Income Inclusion Rule for those jurisdictions in which the Company failed the transitional safe harbor requirement in its full year 2024 effective tax rate. 29 NOTE 12 – FINANCING ARRANGEMENTS The Company has a five-year senior unsecured multi-currency revolving facility, for an aggregate principal amount of $ 700 million, that expires on May 12, 2028. The Company also has a $ 500 million commercial paper program. The $ 700 million multi-currency revolving credit facility serves as a back-up to the commercial paper facility, resulting in an aggregate of $ 700 million as the total available credit under the commercial paper facility and the multi-currency revolving credit facility. The Company had outstanding borrowings of $ 331 million and $ 225 million under the commercial paper facility at September 30, 2024 and December 31, 2023, respectively, and no outstanding borrowings under the multi-currency revolving credit facility. The Company also has access to $ 38 million in uncommitted short-term financing available under lines of credit from various financial institutions, which is reduced by other outstanding short-term borrowings of $ 13 million. At September 30, 2024, the weighted-average interest rate for short-term debt was 5.6 %. At September 30, 2024, the Company had $ 394 million of borrowings available under lines of credit, including lines available under its short-term arrangements and revolving credit facility. The Company’s revolving credit facility, term loans, and senior notes contain certain affirmative and negative debt covenants relating to the Company's operations and financial condition. At September 30, 2024, the Company was in compliance with all debt covenants. Interest expense, net includes interest income of $ 5 million and $ 4 million for the three months ended September 30, 2024 and 2023, respectively. Interest expense, net includes interest income of $ 15 million and $ 11 million for the nine months ended September 30, 2024 and 2023, respectively. Interest income primarily relates to interest-bearing cash equivalents and customer financing for the Company’s direct-to-consumer aligner solutions. 30 NOTE 13 – GOODWILL AND INTANGIBLE ASSETS The Company's policy is to assess goodwill and indefinite-lived intangible assets for impairment annually as of April 1, with more frequent assessments if events or changes in circumstances indicate the asset might be impaired. Based on the annual test performed on April 1, 2024, it was previously determined that the fair values of the Company’s reporting units and indefinite-lived intangible assets more likely than not exceeded their carrying values, resulting in no impairment. In the quarter ended September 30, 2024, the Company identified indicators of a more likely than not impairment for two of its reporting units, Orthodontic Aligner Solutions and Implant & Prosthetic Solutions, which together comprise all of the Orthodontic and Implant Solutions segment. The decline in fair value for the Orthodontic Aligner Solutions reporting unit was driven by adverse impacts from legislative trends pertaining to the Company’s direct-to-consumer aligner business, specifically the Company’s experience of slower than expected improvements in conversion rates for new aligner customers in the third quarter as the Company continued to modify its operating model in response to those trends. Laws relating to teledentistry enacted in Florida and Illinois during the third quarter, and the potential for similar laws to be introduced in other states, required adjustments to the Company’s process for engaging with customers which resulted in a decline in forecasted revenues in the near term, as well as a longer-term decline in operating margins for the business. The reduction in fair value was also the result of continued macroeconomic pressures and weaker than expected demand for the direct-to-consumer business. The reduction in fair value for the Implant & Prosthetic Solutions reporting unit was driven by weakened demand, particularly in North American and European markets, in conjunction with competitive pressures and adverse impacts of ongoing global conflicts in certain markets, as well as lower long-term expectations for volumes of lab materials. These factors contributed to reduced forecasted revenues, lower operating margins, and reduced expectations for future cash flows in the near term for both reporting units. The higher inflationary environment has impacted the discretionary spending behavior of the Company’s customers more generally, further reducing global demand for certain products in favor of lower cost options. For the goodwill impairment test as of September 30, 2024, the fair values of the Orthodontic Aligner Solutions and Implant & Prosthetic Solutions reporting units were computed using a discounted cash flow model with inputs developed using both internal and market-based data. The discounted cash flow model uses ten -year forecasted cash flows plus a terminal value based on capitalizing the last period's cash flows using a perpetual growth rate. Significant assumptions used in the discounted cash flow model included, but were not limited to, discount rates ranging from 9.5 % to 10.0 %, revenue growth rates (including perpetual growth rates), operating margin percentages, and net working capital changes of each respective reporting unit's business. As a result, the Company recorded pre-tax goodwill impairment charges as of September 30, 2024 of $ 145 million for the Orthodontic Aligner Solutions reporting unit and $ 359 million for the Implant & Prosthetic Solutions reporting unit, both within the Orthodontic and Implant Solutions segment. The impairment charge related to the Orthodontic Aligner Solutions reporting unit resulted in a full write-off of the remaining goodwill balance for this reporting unit. As the fair value of the Implant & Prosthetic Solutions reporting unit approximates its carrying value as of September 30, 2024, any further decline in key assumptions could result in additional impairment in future periods. The remaining goodwill associated with the Implant & Prosthetic Solutions reporting unit was $ 814 million as of September 30, 2024. Based on quantitative and qualitative analyses performed for the other reporting units and the Company’s indefinite-lived intangible assets, the Company believes there is no indication that the carrying value more likely than not exceeds the fair value in each case as of September 30, 2024. For the Company's reporting units that were not impaired, the Company applied a hypothetical sensitivity analysis by increasing the discount rate of these reporting units by 50 basis points. The results of this sensitivity analysis at September 30, 2024 indicate that none of the other reporting units would be impaired. The fair values of certain indefinite-lived intangible assets within the Connected Technology Solutions segment continued to approximate carrying values as of September 30, 2024. Any further decline in key assumptions could result in additional impairments in future periods. The carrying value of these assets within the Connected Technology Solutions segment was $ 211 million as of September 30, 2024. There is a risk of future impairment charges if there is a decline in the fair value of the reporting units or indefinite-lived intangible assets as a result of, among other things, actual financial results that are lower than forecasts, an adverse change in valuation assumptions, a decline in equity valuations, increases in interest rates, or changes in the use of intangible assets. There can be no assurance that the Company’s future asset impairment testing will not result in a material charge to earnings. Impairment during the Three Months Ended March 31, 2024 In the three months ended March 31, 2024, the Company identified indicators of a more likely than not impairment related to certain indefinite-lived imaging product trade names within the Connected Technology Solutions segment. The decline in fair 31 value of these indefinite-lived trade names was driven by declines in volumes during the three months ended March 31, 2024, which was due in part to a loss in market share from competitive pricing pressures, as well as unfavorable economic conditions in certain markets. These factors contributed to a reduction in forecasted revenues in the near term. The trade names were evaluated for impairment using an income approach, specifically a relief from royalty method. As a result, the Company recorded an indefinite-lived intangible asset impairment charge of $ 6 million for the three months ended March 31, 2024. Impairment during the Three Months Ended September 30, 2023 In the quarter ended September 30, 2023, the Company identified indicators of a more likely than not impairment related to its Connected Technology Solutions reporting unit, which comprises all the Connected Technology Solutions segment. The decline in fair value for this reporting unit was driven by adverse macroeconomic factors because of weakened demand, particularly in European markets, and increased discount rates. These factors contributed to reduced forecasted revenues, lower operating margins, and reduced expectations for future cash flows in the near term, particularly in relation to demand for products which are commonly financed by end customers and are therefore adversely impacted by an environment of higher interest rates. The reporting unit was evaluated for impairment using an income approach, specifically a discounted cash flow model. As a result, the Company recorded a pre-tax goodwill impairment charge for the three months ended September 30, 2023 related to the Connected Technology Solutions reporting unit of $ 291 million, resulting in a full write-off of the remaining goodwill balance for the Connected Technology Solutions segment. This charge was recorded in Goodwill and intangible asset impairment in the Consolidated Statement of Operations. Additionally, in conjunction with the third quarter test in 2023, the Company conducted an impairment test on the long-lived intangible assets related to the businesses within the Connected Technology Solutions reporting unit within the Connected Technology Solutions segment. The Company also identified an indicator of impairment for the indefinite-lived intangible assets within the Implant & Prosthetic Solutions reporting unit within the Orthodontic and Implant Solutions segment and determined certain trade names and trademarks were impaired. These indefinite-lived intangible assets were evaluated for impairment using an income approach, specifically a relief from royalty method. As a result, the Company recorded indefinite-lived intangible asset impairment charges of $ 14 million and $ 2 million for the Connected Technology Solutions and Orthodontic and Implant Solutions segments, respectively, for the three months ended September 30, 2023. The impairment charge was primarily driven by macroeconomic factors such as weakened demand, higher cost of capital, and cost inflation, which are contributing to reduced forecasted revenues. These charges were recorded in Goodwill and intangible asset impairment in the Consolidated Statements of Operations. A reconciliation of changes in the Company’s goodwill by reportable segment were as follows: (in millions) Connected Technology Solutions Essential Dental Solutions Orthodontic and Implant Solutions Wellspect Healthcare Total Balance at December 31, 2023 Goodwill $ 291 $ 840 $ 1,323 $ 275 $ 2,729 Accumulated impairment losses (a) ( 291 ) — — — ( 291 ) Goodwill, net at December 31, 2023 — 840 1,323 275 2,438 Impairment — — ( 504 ) — ( 504 ) Foreign Currency Translation — 2 ( 5 ) 6 3 Balance at September 30, 2024 Goodwill $ 291 $ 842 $ 1,318 $ 281 $ 2,732 Accumulated impairment losses (a) $ ( 291 ) $ — $ ( 504 ) $ — $ ( 795 ) Goodwill, net at September 30, 2024 $ — $ 842 $ 814 $ 281 $ 1,937 (a) The Company realigned segments in 2023, and at that time, there was an accumulated impairment loss that was not allocated to the new segments. 32 Identifiable definite-lived and indefinite-lived intangible assets were as follows: September 30, 2024 December 31, 2023 (in millions) Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Developed technology and patents $ 1,702 $ ( 1,110 ) $ 592 $ 1,697 $ ( 1,006 ) $ 691 Trade names and trademarks 272 ( 111 ) 161 271 ( 102 ) 169 Licensing agreements 30 ( 28 ) 2 30 ( 27 ) 3 Customer relationships 1,073 ( 737 ) 336 1,070 ( 680 ) 390 Total definite-lived 3,077 ( 1,986 ) 1,091 3,068 ( 1,815 ) 1,253 Indefinite-lived trade names and trademarks 442 — 442 447 — 447 In-process R&D 5 — 5 5 — 5 Total indefinite-lived 447 — 447 452 — 452 Total identifiable intangible assets $ 3,524 $ ( 1,986 ) $ 1,538 $ 3,520 $ ( 1,815 ) $ 1,705 In 2021, the Company purchased certain developed technology rights for an initial payment of $ 3 million and minimum guaranteed contingent payments of $ 17 million to be made upon reaching certain regulatory and commercial milestones. The contingent payments are not considered probable as of September 30, 2024. 33 NOTE 14 – COMMITMENTS AND CONTINGENCIES Contingencies On December 19, 2018, a putative class action was filed in the U.S. District Court for the Eastern District of New York against the Company and certain individual defendants. The case has been narrowed since its inception. The plaintiff’s remaining claims are that the Company and certain individual defendants violated U.S. securities laws by making material misrepresentations and omitting required information in the December 4, 2015 registration statement filed with the SEC in connection with the 2016 merger of Sirona Dental Systems Inc. (“Sirona”) with DENTSPLY International Inc. (the “Merger”) and that the defendants failed to disclose, among other things, that a distributor had purchased excessive inventory of legacy Sirona products. In addition, the plaintiff alleges that the defendants violated U.S. securities laws by making false and misleading statements in quarterly and annual reports and other public statements between May 6, 2016 and August 7, 2018. The plaintiff asserts claims on behalf of a putative class consisting of all purchasers of the Company's stock during the period from December 8, 2015 through August 6, 2018. The Company moved to dismiss the amended complaint on August 15, 2019. The plaintiff filed its second amended complaint on January 22, 2021, and the Company filed a motion to dismiss the second amended complaint on March 8, 2021, with briefing on the motion fully submitted on May 21, 2021. The Company’s motion to dismiss was denied in a ruling by the Court on March 29, 2023, and the Company’s answer to the second amended complaint was filed on May 12, 2023. On September 29, 2023, the plaintiff filed a motion for class certification. The Company’s opposition to the plaintiff's motion for class certification was filed on February 8, 2024, the plaintiff’s reply was filed on May 10, 2024, the Company’s sur-reply in further opposition was filed on September 6, 2024, and the plaintiff was granted leave to file a sur-sur reply on October 7, 2024. On June 7, 2024, the Company served a motion for judgment on the pleadings seeking dismissal of additional portions of the amended complaint. The plaintiff served its opposition on July 26, 2024, and the motion was fully briefed and filed on August 16, 2024 upon the filing of the Company’s reply. The parties have been engaging in settlement discussions with the assistance of a mediator, but no settlement has been reached. At this stage, the Company has recognized a liability as of September 30, 2024, with an offsetting insurance receivable, and with no impact to the income statement in the three and nine months ended September 30, 2024. On June 2, 2022, the Company was named as a defendant in a putative class action filed in the U.S. District Court for the Southern District of Ohio captioned City of Miami General Employees’ & Sanitation Employees’ Retirement Trust v. Casey, Jr. et al., No. 2:22-cv-02371, and on July 28, 2022, the Company was named as a defendant in a putative class action filed in the U.S. District Court for the Southern District of New York captioned San Antonio Fire and Police Pension Fund v. Dentsply Sirona Inc. et al., No. 1:22-cv-06339 (together, the “Securities Litigation”). The complaints in the Securities Litigation are substantially similar and both allege that, during the period from June 9, 2021 through May 9, 2022, the Company, Mr. Donald M. Casey Jr., the Company’s former Chief Executive Officer, and Mr. Jorge Gomez, the Company’s former Chief Financial Officer, violated U.S. securities laws by, among other things, making materially false and misleading statements or omissions, including regarding the manner in which the Company recognized revenue tied to distributor rebate and incentive programs. On March 27, 2023, the Court in the Southern District of Ohio ordered the transfer of the putative class action to the Southern District of New York (the “Court”). On June 1, 2023, the Court consolidated the two separate actions under case No. 1:22-cv-06339 and appointed the City of Birmingham Retirement and Relief System, the El Paso Firemen & Policemen’s Pension Fund, and the Wayne County Employees’ Retirement System as Lead Plaintiffs for the putative class. Lead Plaintiffs filed an amended class action complaint on July 28, 2023 (the “Amended Complaint”). In addition to asserting the same claims against the Company, Mr. Casey, and Mr. Gomez, the Amended Complaint added the Company’s former Chief Accounting Officer, Mr. Ranjit S. Chadha, as a defendant (collectively, “Defendants”). On October 10, 2023, Defendants filed a motion to dismiss the Amended Complaint. Lead Plaintiffs’ opposition to Defendants’ motion to dismiss was filed on December 8, 2023, and Defendants’ reply was filed on January 8, 2024. The motion to dismiss was granted as to Mr. Chadha and granted in part and denied in part as to the Company, Mr. Casey, and Mr. Gomez in a ruling by the Court on May 1, 2024. The Company’s answer to the Amended Complaint was filed on May 21, 2024. In addition to the Securities Litigation, as previously disclosed, the Company voluntarily contacted the SEC following the Company’s announcement on May 10, 2022 of the internal investigation by the Audit and Finance Committee of the Company’s Board of Directors. The Company continues to cooperate with the SEC regarding this matter. Separately, on July 13, 2023, Dentsply Sirona stockholder George Presura filed a shareholder derivative suit in the Delaware Court of Chancery captioned George Presura, Derivatively on Behalf of Nominal Defendant Dentsply Sirona Inc. v. Donald M. Casey Jr. et al. and Dentsply Sirona, Inc., No. 2023-0708-NAC (the “Presura Derivative Litigation”). The complaint, filed derivatively on behalf of the Company, asserts claims against current and former members of the Company’s Board of Directors and current and former executive officers, including Messrs. Casey and Gomez. The derivative complaint in this case contains allegations similar to those in the Securities Litigation, and it alleges that during the period from June 9, 2021 34 through July 13, 2023, various of the defendants breached fiduciary duties, committed corporate waste, and misappropriated information to conduct insider trading by making materially false and misleading statements or omissions regarding the Company’s recognition of revenue tied to distributor rebate and incentive programs and distributor inventory levels. On August 4, 2023, the Delaware Court of Chancery stayed the Presura Derivative Litigation until the earlier of public announcement of a settlement of the Securities Litigation or resolution of the pending motion to dismiss in the Securities Litigation. Additionally, on March 26, 2024, Dentsply Sirona stockholder Calvin Snee filed a shareholder derivative suit in the Delaware Court of Chancery captioned Calvin Snee, derivatively on behalf of Dentsply Sirona Inc. v. Donald M. Casey Jr., et al. and Dentsply Sirona Inc, No. 2024-0308 (the “Snee Derivative Litigation”). The complaint, filed derivatively on behalf of the Company, asserts claims against current and former members of the Company’s Board of Directors and current and former executive officers, including Messrs. Casey and Gomez. The derivative complaint in this case contains allegations similar to those in the Presura Derivative Litigation and the Securities Litigation, and it alleges that beginning in 2021, various of the defendants breached fiduciary duties, misappropriated information to conduct insider trading, and were unjustly enriched by making materially false and misleading statements or omissions regarding the Company’s recognition of revenue tied to distributor rebate and incentive programs and distributor inventory levels. On May 2, 2024, the Delaware Court of Chancery issued an order consolidating and staying the Presura Derivative Litigation and Snee Derivative Litigation. On July 19, 2024, Dentsply Sirona stockholder Frank Manfre filed a shareholder derivative suit in the Delaware Court of Chancery captioned Frank Manfre, derivatively on behalf of nominal defendant Dentsply Sirona Inc. v. Donald M. Casey Jr. et al. and Dentsply Sirona Inc., No. 2024-0763 (the “Manfre Derivative Litigation”). The complaint asserts claims against current and former members of the Company’s Board of Directors and current and former executive officers, including Messrs. Casey and Gomez. The complaint in this case contains allegations similar to those in the Snee Derivative Litigation, the Presura Derivative Litigation, and the Securities Litigation, and it alleges that beginning in 2021, various of the defendants breached fiduciary duties, misappropriated information to conduct insider trading, and were unjustly enriched by making materially false and misleading statements or omissions regarding the Company’s recognition of revenue tied to distributor rebate and incentive programs and distributor inventory levels. On September 19, 2024, the Delaware Court of Chancery issued an order consolidating and staying the Manfre Derivative Litigation, Presura Derivative Litigation, and Snee Derivative Litigation. On March 21, 2023, Mr. Carlo Gobbetti filed a claim in the Milan Chamber of Arbitration against Dentsply Sirona Italia S.r.l. (“DSI”), Italy, a wholly owned subsidiary of the Company, seeking a total of € 28 million for the alleged failure to pay a portion of the purchase price pursuant to a Share Purchase Agreement, dated October 8, 2012 (the “SPA”), in which Sirona Dental Systems, S.r.l., which at the time of execution of the SPA was a wholly-owned subsidiary of Sirona Dental Systems, Inc., acquired all of the shares of MHT S.p.A., an Italian corporation, from Mr. Gobbetti, and various other sellers. Sirona Dental Systems S.r.l. merged into Dentsply Italia S.r.l. in 2018 (the surviving entity is now Dentsply Sirona Italia S.r.l.). Under the SPA, a portion of the purchase price equal to € 7 million was required to be deposited into an escrow account (the “Escrow Account”) and released to Mr. Gobbetti and the other sellers upon the satisfaction of certain conditions, including the delivery by July 2013 of a new prototype of an MHT S.p.A. camera which had to meet certain specifications. In connection with the closing of the share purchase transaction, the SPA was supplemented by a Facility Agreement, also dated October 8, 2012 (the “FA”), which specifically set out the mechanics of payment and release of the proceeds of the Escrow Account. The Austrian notary public, Mr. Gottfried Schachinger, acting as escrow agent, Mr. Gobbetti, and SIRONA Holdings GmbH, an affiliate of Sirona Dental Systems, Inc. which paid the € 7 million into the Escrow Account, were parties to the FA. The FA is subject to Austrian law and to the jurisdiction of the Court of Salzburg in Austria. Mr. Gobbetti claims that he is entitled to receive the € 7 million outstanding balance of the purchase price under the SPA, plus € 21 million for damages incurred as a consequence of the failure to make the payment. Mr. Gobbetti claims that he has a right to receive the full purchase price under the SPA even if the conditions set out in the SPA to deliver a prototype of the MHT S.p.A. camera by July 2013 were not met. On May 15, 2023, DSI filed its initial statement of defense denying that Mr. Gobbetti and the other sellers were entitled to receive the funds deposited in the Escrow Account and further disputing the allegations. Following the constitution of the arbitral tribunal, hearings were held on September 13, 2023 and January 19, 2024, to illustrate and discuss their respective positions. The parties also developed their arguments in several rounds of defensive briefs. The final submissions were completed on April 15, 2024 and the final hearing for discussion took place on May 8, 2024. On July 22, 2024, the arbitral tribunal rejected all of Mr. Gobbetti’s claims, ruling that the Company had met its contractual obligations under the SPA, particularly regarding the balance of the purchase price. The arbitral tribunal also dismissed Mr. Gobbetti’s claims in tort and those pertaining to the FA for lack of jurisdiction and lack of capacity for the Company to be sued. 35 The arbitral tribunal observed that such claims should have been brought against SIRONA Holdings GmbH, which is a party to the FA but not to the SPA, before the Court of Salzburg in Austria based on the jurisdictional clause of the FA. The arbitration award has been duly served to Mr. Gobbetti and his time to appeal expires on December 3, 2024. Except as noted above, no specific amounts of damages have been alleged in these lawsuits. The Company will continue to incur legal fees in connection with these pending cases, including expenses for the reimbursement of legal fees of present and former officers and directors under indemnification obligations. The expense of continuing to defend such litigation may be significant. The Company intends to defend these lawsuits vigorously, although the Company may elect to settle certain litigation matters, but there can be no assurance that the Company will be successful in any defense or that matters can be settled on terms favorable to the Company. If any of the lawsuits are decided adversely, the Company may be liable for significant damages directly or under its indemnification obligations, which could adversely affect the Company's business, results of operations and cash flows. At this stage, the Company has accrued losses which are assessed to be more likely than not, along with related insurance receivables, but the Company is unable to assess whether any incremental material loss or adverse effect is reasonably possible as a result of these lawsuits or estimate the range of any potential loss. The Internal Revenue Service (“IRS”) is conducting an examination of the Company's U.S. federal income tax returns for the tax years 2015 and 2016. The Company received a Notice of Proposed Adjustment in April 2023 and a Revenue Agent Report in January 2024 from the IRS examination team proposing an adjustment related to an internal reorganization completed in 2016 with respect to the integration of certain operations of Sirona Dental Systems, Inc. following its acquisition in 2016. Although the proposed adjustment does not result in any additional federal income tax liability for the internal reorganization, if sustained, the proposed adjustment would result in the Company owing additional federal income taxes on a distribution of $ 451 million related to a stock redemption that occurred after the internal reorganization was completed in 2016. The amount of additional federal income taxes due for 2016 would be approximately $ 2 million, excluding interest. The proposed adjustment, if sustained, would also result in a loss of foreign tax credits carried forward to later tax years. The Company believes that it accurately reported the federal income tax consequences of the internal restructuring and stock redemption in its tax returns and in April 2024, submitted an administrative protest with the IRS Independent Office of Appeals contesting the examination team’s proposed adjustments. The IRS examination team provided the Company with a rebuttal to the Company’s administrative protest during August 2024 and informed the Company that the dispute would be forwarded to the IRS Independent Office of Appeals. The Company intends to vigorously defend its reported positions and believes that it is more likely than not that its positions will be sustained. The Company has not accrued a liability relating to the proposed tax adjustments. However, the outcome of this dispute involves a number of uncertainties, including those relating to the application of the Internal Revenue Code and other federal income tax authorities and judicial precedent. Accordingly, there can be no assurance that the dispute with the IRS will be resolved favorably. The Company intends to vigorously defend its positions and pursue related appeals in the above-described pending matters. In addition to the matters disclosed above, the Company is, from time to time, subject to a variety of litigation and similar proceedings incidental to its business. These legal matters primarily involve claims for damages arising out of the use of the Company’s products and services and claims relating to intellectual property matters including patent infringement, employment matters, tax matters, commercial disputes, competition and sales and trading practices, personal injury, and insurance coverage. The Company may also become subject to lawsuits as a result of past or future acquisitions or as a result of liabilities retained from, or representations, warranties or indemnities provided in connection with, divested businesses. Some of these lawsuits may include claims for punitive and consequential, as well as compensatory, damages. Except as otherwise noted, the Company generally cannot predict what the eventual outcome of the above-described pending matters will be, what the timing of the ultimate resolution of these matters will be, or what the eventual loss, fines or penalties related to each pending matter may be. Based upon the Company’s experience, current information, and applicable law, it does not believe that these proceedings and claims will have a material adverse effect on its consolidated results of operations, financial position, or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to the Company’s business, financial condition, results of operations, or liquidity. While the Company maintains general, product, property, workers’ compensation, automobile, cargo, aviation, crime, fiduciary and directors’ and officers’ liability insurance up to certain limits that cover certain of these claims, this insurance may be insufficient or unavailable to cover such losses. In addition, while the Company believes it is entitled to indemnification from third parties for some of these claims, these rights may also be insufficient or unavailable to cover such losses. 36 Commitments Purchase Commitments The Company has certain non-cancelable future commitments primarily related to long-term supply contracts for key components and raw materials. At September 30, 2024, non-cancelable purchase commitments were as follows: (in millions) 2024 $ 73 2025 171 2026 69 2027 43 2028 41 Thereafter — Total $ 397 The above information should be read in conjunction with Part II, Item 7 “Contractual Obligations” and Part II, Item 8, Note 21, Commitments and Contingencies, in the Company’s 2023 Form 10-K. The table above includes commitments under the Company’s agreement with a cloud services provider supporting the Company’s digital platform which requires minimum purchases totaling $ 89 million through 2028. Off-Balance Sheet Arrangements As of September 30, 2024, the Company had no material off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on the Company’s consolidated financial condition, results of operations, liquidity, capital expenditures or capital resources other than certain items disclosed in the sections above. Indemnification In the normal course of business to facilitate the sale of the Company’s products and services, the Company indemnifies certain parties, including customers, vendors, lessors, service providers, and others, with respect to certain matters, including, but not limited to, services to be provided by or for the Company, and intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with its directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. Several of these agreements limit the time within which an indemnification claim can be made and the amount of the claim. It is not possible to make a reasonable estimate of the maximum potential amount of indemnification under these indemnification agreements due to the unique facts and circumstances involved in each particular agreement. Additionally, the Company has a limited history of prior indemnification claims, and the payments the Company has made under such agreements have not had a material effect on its results of operations, cash flows or financial position. As of September 30, 2024, the Company did not have any material indemnification claims that were probable or reasonably possible. However, to the extent that valid indemnification claims arise in the future, future payments by the Company could be significant and could have a material adverse effect on the Company’s results of operations or cash flows in a particular period. 37 NOTE 15 – SUBSEQUENT EVENTS On October 24, 2024, the Company announced the voluntary suspension of the sale and marketing of its Byte aligner system and impression kits, while the Company conducts a review of certain regulatory requirements related to these products. The Company’s decision was made in communication with the U.S. Food and Drug Administration (the “FDA”). In connection with this review, and the Company’s proactive efforts to continuously improve its processes, the Company has suspended shipment and processing of new and recently placed orders for Byte aligners and impression kits. The Company expects this suspension of sales to have a material impact on the Company’s results of operations. The sales of Byte aligner systems and impression kits represent approximately 5 % of the Company’s revenue for the nine months ended September 30, 2024, and the assets related to the Byte aligner business are approximately 6 % of the Company’s assets at September 30, 2024. The Byte aligner business is included within the Orthodontic and Implant Solutions operating segment. While the Company is evaluating and assessing the appropriate next steps, the Company is unable to estimate the timeframe or provide any assurances that it can return Byte aligners and impression kits to the market. The results of this review may also require the Company to further change or discontinue its current business model and operations of its direct-to-consumer aligner business, which could result in a greater material adverse impact on the Company’s business, financial condition, and results of operations, including asset impairments. In addition, the Company’s failure to promptly resolve these issues or to comply with the U.S. medical device regulatory requirements in general could result in regulatory action being initiated by the FDA that would have a material adverse impact on the Company’s financial status and results of operations. The FDA’s actions could include, among other things, fines, injunctions, consent decrees, civil money penalties, repairs, replacements, refunds, recalls or seizures of products, total or partial suspension of production, the FDA’s refusal to grant future premarket approvals and criminal prosecution. 38 DENTSPLY SIRONA Inc. and Subsidiaries